Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 11
Submit an article Journal homepage
198
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?

Rami Komrokjia Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USACorrespondence[email protected]
,
Najla Al Alia Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
,
Eric Padrona Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
,
Jeffrey Lanceta Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
,
Aziz Nazhab Leukemia Program, Cleveland Clinic, Cleveland, OH, USA
,
David Steensmac Dana-Farber Cancer Institute, Boston, MA, USA
,
Amy DeZernd Kimmel Cancer Center/Johns Hopkins University, Baltimore, MD, USA
,
Gail Roboze Weill Cornell Medical College, New York, NY, USA
,
Guillermo Garcia-Manerof Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
,
Mikkael A. Sekeresb Leukemia Program, Cleveland Clinic, Cleveland, OH, USA
&
David Sallmana Malignant Hematology Department, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
 show all
Pages 2762-2767 | Received 15 Jan 2021, Accepted 25 May 2021, Published online: 11 Jun 2021

References

  • Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010;24(2):443–457.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
  • Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–585.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
  • Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506.
  • Zeidan AM, Hu X, Long JB, et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: a large population-based study. Cancer. 2017;123(19):3754–3762.
  • Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30(3):649–657.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98(7):1067–1072.
  • Gore S, Fenaux P, Santini V, et al. Time-dependent decision analysis: stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS. J Clin Oncol. 2010;28(15 Suppl.):6503.
  • Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(4):496–508.
  • Komrokji RS, DeZern AE, Zell K, et al. Validation of International Working Group (IWG) response criteria in higher-risk myelodysplastic syndromes (MDS): a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Blood. 2015;126(23):909–909.
  • Polgarova K, Vargova K, Kulvait V, et al. Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients–responders. Oncotarget. 2017;8(67):111966–111978.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.